Premium
Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases
Author(s) -
BanimohamadShotorbani Behnaz,
Farajpour Hekmat,
Sefat Farshid,
Khosroshahi Shiva Ahdi,
Shafaei Hajar,
Heidari keshel Saeed
Publication year - 2021
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.27729
Subject(s) - mesenchymal stem cell , stromal cell , extracellular vesicles , microvesicles , lung , respiratory system , medicine , cell , biology , extracellular , cancer research , immunology , pathology , microbiology and biotechnology , biochemistry , microrna , gene
At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in treatment of several diseases. Not only mesenchymal stromal cells of several tissues, but also their secreted extracellular vesicles and even secretome indicated beneficial therapeutic function. All of these three options were studied for treatment of COVID‐19 as well as those respiratory diseases that have similar symptom. Fortunately, most of the outcomes were promising and optimistic. In this paper, we review in‐vivo and clinical studies which have been used different sources of mesenchymal stromal cell, secreted extracellular vesicles, and secretome to improve and treat symptoms of COVID‐19 and similar lung diseases.